1	A Cost-effectiveness analysis of Nivolumab plus chemotherapy for the first-line treatment of
2	locally advanced or metastatic gastric/GEJ/oesophageal adenocarcinoma in the United States of
3	America
4	Jin Zhou <sup>1¶</sup> , Yukai Tang <sup>1¶</sup> , Geli Li <sup>2*</sup>
5	<sup>1</sup> Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan,
6	China
7	<sup>2</sup> Department of Oncology, Affiliated Hospital of Xiangnan University, Chenzhou, Hunan, China
8	¶1st set of equal contributors.
9	*Corresponding author
10	E-mail: 19165664057@163.com
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	NOTE: This preprint reports new research that has not been certified by near review and should not be used to guide clinical practical

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

Abstract: Background: Nivolumab in combination with chemotherapy significantly improves survival in patients with gastric/gastroesophageal junction (G/GEJ)/esophageal adenocarcinoma. The purpose of this study was to evaluate the cost-effectiveness of Nivolumab plus chemotherapy for G/GEJ/esophageal adenocarcinoma. **Methods:** A Markov model was developed on the basis of the US healthcare payers' perspectives. We estimated the costs and summarised their effectiveness as quality-adjusted life-years (QALYs). One-way and probabilistic sensitivity analyses were conducted to explore the impact of uncertainties on the cost-effectiveness's results. **Results:** The incremental cost-effectiveness (ICER) Nivolumab ratios for plus chemotherapy(\$149636.97,1.24QALYs) verus chemotherapy(\$13941.06,0.75QALYs) is \$135695.91 and the QALYs is 0.49. **Conclusions:** Evidence suggests that Nivolumab plus chemotherapy a for the first-line treatment of locally advanced or metastatic gastric/GEJ/oesophageal adenocarcinoma may be not a cost-effective choice. **Keywords:** Cost-Effectiveness; Nivolumab; metastatic gastric/GEJ/oesophageal adenocarcinoma; Markov model

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

1. Background Gastric/gastroesophageal junction(G/GEJ)/oesophageal adenocarcinoma can be regarded as a relatively common cancer worldwide, and its incidence is increasing day by day. Nowadays, gastric cancer is the fifth most common cancer in the world, and its fatality rate ranks the third among all cancers. From the perspective of geographical distribution, the incidence has increased significantly in east Asia in recent years, as has North America (1). At present, surgery is still the preferred treatment for G/GEJ/oesophageal adenocarcinoma. However, the prognosis is bleak and the postoperative recurrence rate reaches 50%-70% (2, 3). For those patients with unresectable advanced stage, other methods can only be sought. In recent years, many studies have focused on improving the prognosis of this group of patients. At present, fluorouracil, platinum and paclitaxel are the main chemotherapy drugs for advanced G/GEJ/oesophageal adenocarcinoma with negative HER-2, but their therapeutic effect is not optimistic, and the survival time of most patients receiving chemotherapy is not more than 1 year (4-6). Besides, after the use of targeted therapy combined with chemotherapy for these patients, their survival was not significantly improved compared with chemotherapy (7-10). Nivolumab is a PD-1 inhibitor. As PD-L1 is expressed more obviously in tumor cells and tumor immune cells than in normal cells, PD-1 inhibitor has been gradually promoted to a higher position in tumor therapy. Nivolumab has shown good efficacy in the treatment of many cancers such as non-small cell lung cancer and renal cell carcinoma (11, 12). Therefore, the Checkmate 649, a phase 3 trial, has been carried out, in which researchers recruited a group of advanced, unresectable and HER-2 negative patients and randomly divided them into two groups. In addition

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

to the analysis of all patients, PD-L1 CPS patients were singled out for follow-up analysis. Then, the prognosis of the two groups of patients was compared between the combination chemotherapy with Nivolumab and chemotherapy alone. In the Result, For patients with PD-L1 CPS<sub>2</sub>5, median OS improvement was 3 months (14.4 months [95% CI 13.1 to 16.2]vs 11.1 month [10.0 to 12.1]); Median PFS was 7.7 months (95% CI 7.0 to 9.2) for combination chemotherapy with Nivolumab compared with 6.05 months (5.0 to 6.9) for chemotherapy. For all randomized patients, the median OS was 13.1 months (IQR, 6.7 to 19.1) in the Nivolumab group and 11.1 months (5.8 to 16.1) in the chemotherapy group. In conclusion, Compared with chemotherapy alone, Nivolumab combined with chemotherapy significantly improved patient survival, especially in patients with PD-L1 CPS>5 (13). A cost-benefit analysis is necessary before a new drug becomes an approved method of treatment for many patients. Hence, in this study, based on the results of the Checkmate649 clinical trial, we established an economic model to evaluate the cost-effectiveness of Nivolumab in combination with chemotherapy in G/GEJ/oesophageal adenocarcinoma.

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

2. Materials and Methods 2.1 Population CheckMate 649 is a randomized phase 3 trial involving 1581 patients from From March 2017 through April 2019 in all over the world. Median progression-free survival (7·7 months [95% CI 7·0–9·2]) was significantly longer in the nivolumab plus chemotherapy group than in the chemotherapy group (6.05 months [95% CI 5.6–6.9]) in patients with PD-L1 CPS ≥5, as was median overall survival analysis (14·4 months [95% CI 13·1–16·2] vs 11·1 months [10·0–12·1], respectively) in patients with PD-L1 CPS ≥5). Our data were based on clinical characteristics of CheckMate 649 subjects aged 18 years or older with previously untreated, unresectable advanced or metastatic gastric, GEJ, or oesophageal adenocarcinoma, regardless of PD-L1 expression. We focused on the third phase of the CheckMate 649 study. In the total number of people in this trial, there are 955 patients with PD-L1 CPS > 5. Among them, 473 participants were in the experimental group(Nivolumab chemotherapy)and 482 plus the control group(chemotherapy). We conducted a cost-effectiveness analysis for the Nivolumab plus chemotherapy group and chemotherapy group to provide a foundation for their different treatment. The research methods refer to the consolidated health economic evaluation reporting standards (CHEERS)( see Supplementary Information S1). 2.2 The Model's Structure The study used TreeAge Software 2021 (TreeAge Software, Inc, Williamstown, Massachusetts) to programme a multi-state Markov model. The purpose was to evaluate the

cost-effectiveness of Nivolumab plus chemotherapy and chemotherapy in patients with untreated,

unresectable advanced or metastatic gastric, GEJ, or oesophageal adenocarcinoma. This was due to the Markov model being able to provide more flexible modelling assumptions. (14) The multiple health states include PFS, progressive disease state (PD) and death. Assuming that patients in a certain state only make one state transition in a cycle, once the patients are in the PD state, they cannot return to the PFS state. Similarly, the patients in the dead state cannot transition to other states. The specific transition relationships are shown in Figure 1. We assumed that all the patients were in a PFS healthy state at the model's initial stage. The patients were treated with Nivolumab plus chemotherapy or chemotherapy according to their groupings. When the disease progresses, the follow-up treatment plan in the CheckMate 649 clinical trial is used for treatment until the patient's death.




Figure 1. Markov state transition model.

We developed a Markov model to simulate the patient's entire life course and evaluate the cost and effectiveness of first-line therapy for patients with advanced/metastatic gastric, GEJ, or oesophageal adenocarcinoma. In the CheckMate 649 clinical trial, the median survival time of the experimental group was 14.4 months, the control group was 11.1 months, and the overall time of the study is approximately 2 years. The effect of immunotherapy has a delayed effect and may continue to work beyond the treatment period. It should be analyzed from long-term data to avoid inaccuracy and uncertainty of results(15, 16). As the result of that, with reference to the dosing

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

cycle of the CheckMate 649 clinical trial, we set the cycle of the Markov model to three weeks and the time range was 10 years. Approximately 99% of patients were in the absorption state.(17) A half-circle correction was conducted to simulate the transfer process more accurately. Simultaneous simulation analysis of the cost and utility is performed to estimate the cumulative total cost and health outcomes within the cohort's time frame.(18, 19) The research was based on the American payers' perspectives, with a 3% discount on costs and utilities. (20) According to the World Health Organization, ICER is acceptable when it is below three times GDP per capita(21). This study will use three times of the United States's triple GDP per capita in 2021(\$69219.5) as the threshold(https://fred.stlouisfed.org/series/A939RC0Q052SBEA). The WTP is assumed to be \$207659. The research indicators include the costs, life-years (LYs), quality-adjusted life-years(QALYs), and the incremental cost-effectiveness ratios (ICERs). 2.3 The Model's Survival and Progression Risk Estimates The original data for constructing the model were obtained from the CheckMate 649 clinical trial. When some data were unavailable, we referred to the related published literature. The GetData Graph Digitiser (version 2.26; http://getdata-graph-digitizer.com/download.php) was used to extract the Kaplan-Meier curve's data of the PFS and OS in the Nivolumab plus chemotherapy group and the chemotherapy group. We also referred to the algorithm of Guyot et al. who refers to the pseudo-individual patient's data reconstructed by R software (version 4.1.0; https://www.r-project.org/).(22) This was combined with the Akaike Information Criterion (AIC) and the Bayesian Information Criterion(BIC) to select the Log-logistic distribution that fitted the survival curve for Nivolumab plus chemotherapy and chemotherapy respectively after the reconstruction(eTable 1).(23) The distribution has a higher flexibility and estimated

#### correlations.(24, 25)

152

153

154

155

156

157

158

### Table 1 Base-case Analysis

Nivolumab plus							
Parameters	chemotherapy	Chemotherapy					
QALYs	0.75	0.27					
Total cost \$	13941.06	17565.97					
ICER \$/QALYb	276799.67						
WTP \$/QALY	190239						

# Tornado Diagram - ICER Nivolumab plus chemotherapy vs. Chemotherapy




Figure 2. Tornado diagram for one-way sensitivity analysis.

Abbreviation: SD= Stable disease; PD= Disease progression; ICER= Incremental cost-effectiveness ratio.

### 2.4 The Utility and Cost Estimates

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

During the follow-up, the CheckMate 649 trial used the Gastric Cancer Subscale (GaCS) to compare quality of life after Nivolumab plus chemotherapy vs chemotherapy as the first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/oesophageal adenocarcinoma.the average health utility (0.797 for PFS and 0.577 for PD) of the patients with gastric cancer/gastroesophageal junction cancer/oesophageal adenocarcinoma in the PFS and PD was obtained by previously published study(26). The top three incidence adverse events(AEs) with grade 3 or above were selected in Nivolumab plus chemotherapy (nivolumab [360 mg every 3 weeks or 240 mg every 2 weeks]-pluschemotherapy[XELOX every 3 weeks or FOLFOX every 2 weeks], nivolumab-plus-ipilimumab) and chemotherapy to be considered to evaluate the loss of the health utility caused by the three to five adverse events(AEs) for simplifying the calculation. The top three incidence adverse events (AEs) with grade 3 or above in Nivolumab plus chemotherapy and chemotherapy are Neutropenia (14%), Decreased platelet count(8%), Proteinuria(5%), Increased blood bilirubin(5%), Increased γ-glutamyltransferase(5%) and Palmar-plantar erythrodysaesthesia syndrome(12%), Hypertension(6%), Increased aspartate aminotransferase (5%), respectively. The costs are reported in 2021 US dollars (US  $1.0 = CNY \times 6.38$ ). Only the direct costs of the medical expenses were considered. This included the cost of the drugs, subsequent treatment costs, management costs, follow-up costs, laboratory examination costs, and the major adverse reactions with grade 3 or above had the top three incidence rates according to CheckMate 649 trial. The drug prices we selected local hospital prices or the price obtained by consulting with the drug supplier. The estimated cost of each drug during the set period is listed in Table 2. The

probability that different treatment groups intend to receive different follow-up treatment and the treatment mode of specific subsequent therapies(systemic therapy other than PD-(L)1 inhibitors, local regional therapy, radiation therapy, surgery, PD-(L)1 inhibitors) are derived from CheckMate 649 trial.

Table 2 Model parameters: baseline values, ranges, and distributions for sensitivity analysis.

## Main model parameters

Table 2 Model parameters: baseline values, ranges, and distributions for sensitivity analysis.

188	Main model parameters	Main mode
188	Main model parameter	Main mode

181

182

183

184

185

186

Variable		References								
(Group:CPS>5 patients)	Baseline value	Minimum Maximum		Distribution	Mean	Standard deviation				
Parameter										
survival										
distribution										
log-logistic PFS	Shape=1.648147						Model fitting			
of N+C	Scale=8.546154	-	-	-	-	-	Model fitting			
log-logistic OS	Shape=1.6508						Model fitting			
of N+C	Scale=14.4888	-	-	-	-	-	Model Inting			
log-logistic PFS	Shape=1.6508						Model fitting			
of C	Scale=14.4888	-	-	-	-	-	Model Inding			
log-logistic OS	Shape=1.7398						Model fitting			
of C	Scale=10.546	-	-	-	-	-	Model Inding			
			Risk f	or main advers	se events					
		Nivolumab plus chemotherapy group								
Neutropenia	0.15	0.12	0.18	Beta	0.15	0.03	Checkmate-649			
Neutrophil count decreased	0.11	0.088	0.132	Beta	0.11	0.022	Checkmate-649			
Anaemia	0.07	0.056	0.084	Beta	0.07	0.014	Checkmate-649			
Diarrhoea	0.05	0.04	0.06	Beta	0.05	0.01	Checkmate-649			
Neutropenia	0.06	0.048	0.072	Beta	0.06	0.012	Checkmate-649			
Neutrophil count decreased	0.03	0.024	0.036	Beta	0.03	0.006	Checkmate-649			
Anaemia	0.02	0.016	0.024	Beta	0.02	0.004	Checkmate-649			
Diarrhoea	0.03	0.024	0.036	Beta	0.03	0.006	Checkmate-649			
			Н	ealth utility sc	ores					
Utility of PFS	0.797	0.6376	0.9564	Beta	0.797	0.1594	[2]			
Utility of PD	0.577	0.4616	0.6924	Beta	0.577	0.1154	[2]			

			Dr	rug cost, \$/per	cycle		
Nivolumab-3w	9957.15	7965.72	11948.58	Gamma	9957.15	1991.43	Drugs
Oxaliplatin-3w	521.82	417.456	626.184	Gamma	521.82	104.364	Drugs
Capecitabine-3w	183.3	146.64	219.96	Gamma	183.3	36.66	Drugs
Nivolumab-2w	6638.1	5310.48	7965.72	Gamma	6638.1	1327.62	Drugs
Oxaliplatin-2w	341.19	272.952	409.428	Gamma	341.19	68.238	Drugs
Leucovorin-2w	185.184	148.1472	222.2208	Gamma	185.184	37.0368	Drugs
Fluorouracil-2w	43.62624	34.90099	52.35149	Gamma	332.148	66.42962	Drugs
Radiotherapy	8998.72	6,636.09	13,160.22	Gamma	8998.72	1799.744	[4]
Surgery	20982	10490	41960	Gamma	20982	4196.4	[7]
Paclitaxel	726.57	581.256	871.884	Gamma	726.57	145.314	Drugs
Docetaxel	215.595	172.476	258.714	Gamma	215.595	43.119	Drugs
Carboplatin	165.51	132.408	198.612	Gamma	165.51	33.102	Drugs
Cisplatin	17.064	13.6512	20.4768	Gamma	17.064	3.4128	Drugs
Ramucirumab	143731	114984.8	172477.2	Gamma	143731	28746.2	Drugs
Pembrolizumab	10739.54	8591.632	12887.45	Gamma	10739.5	2147.908	Drugs
			Exper	nditures on mai	in AEs, \$		
							keynote590 D
Neutropenia	1043	834.4	1251.6	Gamma	1043	208.6	Reynologo 2
110dd oponia	10.15	05 1. 1	1201.0	Guiiiii	10.5	200.0	Reaction Tabl
							redelien rabi
							keynote590 D
Neutrophil	466	372.8	559.2	Gamma	466	93.2	
count decreased							Reaction Tabl
							keynote590 D
Anaemia	1654	1323.2	1984.8	Gamma	1654	330.8	
							Reaction Tabl
							keynote590 D
Diarrhoea	3339.64 2	2671.712	4007.568	Gamma	3339.64	667.928	
							Reaction Tabl
F 11							
Follow-up per	59.2	47.36	71.04	Gamma	59.2	11.84	[8]
cycle							
Laboratory per	157.5	126	189	Gamma	157.5	31.5	[9]
cycle Administration							
	69.81	55.848	83.772	Gamma	69.81	13.962	[8]
per cycle				sutility due to	AFc		
Neutropenia	-0.09	-0.072	-0.108	Beta	-0.09	-0.018	[10]
Neutrophil	-0.09	-0.072	-0.108	Deta	-0.09	-0.016	[10]
count decreased	-0.26	-0.208	-0.312	Beta	-0.26	-0.052	
Anaemia	-0.073	-0.0584	-0.0876	Beta	-0.073	-0.0146	[10]
maciilla	-0.073	-0.0304	-0.0070	Deta	-0.073	-0.0140	[10]

Diarrhoea	-0.05	-0.04	-0.06	Beta	-0.05	-0.01	[10]		
	Risk for Subsequent therapy								
		Nivolumab plus chemotherapy group							
Radiotherapy	0.05	0.04	0.06	Beta	0.05	0.01	Checkmate-649		
Surgery	0.02	0.016	0.024	Beta	0.02	0.004	Checkmate-649		
Paclitaxel	0.18	0.144	0.216	Beta	0.18	0.036	Checkmate-649		
Docetaxel	0.02	0.016	0.024	Beta	0.02	0.004	Checkmate-649		
Fluorouracil	0.09	0.072	0.108	Beta	0.09	0.018	Checkmate-649		
Capecitabine	0.03	0.024	0.036	Beta	0.03	0.006	Checkmate-649		
Oxaliplatin	0.04	0.032	0.048	Beta	0.04	0.008	Checkmate-649		
Carboplatin	0.01	0.008	0.012	Beta	0.01	0.002	Checkmate-649		
Cisplatin	0.02	0.016	0.024	Beta	0.02	0.004	Checkmate-649		
Ramucirumab	0.1	0.08	0.12	Beta	0.1	0.02	Checkmate-649		
Nivolumab	0.01	0.008	0.012	Beta	0.01	0.002	Checkmate-649		
Pembrolizumab	0.01	0.008	0.012	Beta	0.01	0.002	Checkmate-649		
				Chemotherap	oy group				
Radiotherapy	0.05	0.04	0.06	Beta	0.05	0.01	Checkmate-649		
Surgery	0.01	0.008	0.012	Beta	0.01	0.002	Checkmate-649		
Paclitaxel	0.21	0.168	0.252	Beta	0.21	0.042	Checkmate-649		
Docetaxel	0.04	0.032	0.048	Beta	0.04	0.008	Checkmate-649		
Fluorouracil	0.14	0.112	0.168	Beta	0.14	0.028	Checkmate-649		
Capecitabine	0.02	0.016	0.024	Beta	0.02	0.004	Checkmate-649		
Oxaliplatin	0.06	0.048	0.072	Beta	0.06	0.012	Checkmate-649		
Carboplatin	0.01	0.008	0.012	Beta	0.01	0.002	Checkmate-649		
Cisplatin	0.03	0.024	0.036	Beta	0.03	0.006	Checkmate-649		
Ramucirumab	0.1	0.08	0.12	Beta	0.1	0.02	Checkmate-649		
Nivolumab	0.03	0.024	0.036	Beta	0.03	0.006	Checkmate-649		
Pembrolizumab	0.04	0.032	0.048	Beta	0.04	0.008	Checkmate-649		

The calculated drug dose are based on the actual clinical trials. In the Nivolumab plus chemotherapy group, the patients received 360 mg of Nivolumab every 3 weeks or 240 mg every 2 weeks and chemotherapy (XELOX [capecitabine 1000 mg/m2 twice daily, days 1-14 and oxaliplatin 130 mg/m<sup>2</sup>, day 1, every 3 weeks] or FOLFOX [leucovorin 400 mg/m<sup>2</sup>, day 1, fluorouracil 400 mg/m<sup>2</sup>, day 1 and 1200 mg/m<sup>2</sup>, days 1-2, and oxaliplatin 85 mg/m<sup>2</sup>, day 1, every 2 weeks]). In the chemotherapy group, the patients received chemotherapy alone. We assumed that the average body surface area was 1.68 m<sup>2</sup>.(27)When patients disease progressed, we

189

190

191

192

193

194

195

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

assumed that all patients who disease progressed had follow-up treatment. It is important to note that the systemic therapy other than PD-(L)1 inhibitors in the subsequent therapies for advanced Gastric cancer, which we chose based on the NCCN 2022.1 guideline, is oxaliplatin, leucovorin plus fluorouracil therapy(oxaliplatin 85 mg/m2 IV on day 1, Leucovorin 200 mg/m2 IV on day 1,2,fluorouracil 2600 mg/m2 IV continuous infusionover 24 hours on day1). 2.5 Sensitivity Analyses A one-way sensitivity analysis was performed to explore the influence of uncertain parameters on the ICER. Each parameter was independently changed by assuming ±20% of the expected value to determine the obvious influence on decision-making. Probabilistic analysis (PSA) was used to randomly sample all the parameters from a specified distribution to further explore the uncertainty and relevance of the model's parameters. According to the parameter type, we selected the appropriate distribution for each uncertain parameter: the cost of the adverse reactions to drugs and treatment is the gamma distribution. The risk of adverse reactions, and the health utility scores including PFS, OS, and AE are the beta distribution. We performed a second-order Monte Carlo simulation of 10,000 iterations and generated a cost-benefit acceptability curve (CEAC) to show that Nivolumab plus chemotherapy is cost-effective with different WTP thresholds.

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

3. Results 3.1 Base-case Analysis The result of base-case analysis about the cost and effectiveness of Nivolumab plus chemotherapy group and chemotherapy group in patients with untreated, unresectable advanced or metastatic gastric, GEJ, or oesophageal adenocarcinoma was shown in Table 1.According to our analysis, the incremental cost of Nivolumab plus chemotherapy (\$149636.97,1.24OALYs) verus chemotherapy(\$13941.06,0.75QALYs) is \$135695.91 and the QALYs is 0.49. The ICER values(\$276799.67) are higher than the United States's triple GDP per capita threshold in 2021 (\$207659).3.2 Sensitivity Analyses A one-way sensitivity analysis was used to test the robustness of the two population model outputs. Under the condition that the input model parameters change by ±20%, the influence of each parameter on the analysis results is explored. The results are presented in the tornado diagram (Figure 2). The sensitivity analysis results demonstrated that the cost of Nivolumab has the most contributed to it. 3.3 Probability sensitivity analysis Probability sensitivity analysis (PSA) is applied to test the bias of the multiple model parameters on the analysis results when the multiple model parameters change simultaneously.

The results are presented through cost-effectiveness acceptability curves (Figure 3) and incremental cost-effectiveness scatterplots (Figure 4). According to the results, we found that the higher the average social willingness to pay, the higher the probability of Nivolumab plus chemotherapy producing the cost effect. Under the condition of a payment threshold of \$207659 per QALY, Probabilistic sensitivity analysis showed that there was 1.49% probability that Nivolumab plus chemotherapy was cost-effective within the fluctuation range of other model parameters in first-line in advanced gastric, GEJ, or oesophageal adenocarcinoma.





Figure 3. Acceptability Curves for the choice of sintilimab plus IBI305 versus sorafenib at

- different WTP thresholds in patients in the treatment of hepatocellular carcinoma.
- 251 Abbreviation: WTP= Willingness to pay.






Figure 4. Incremental cost-effectiveness scatterplots

We also conducted subgroup analysis of the patients with PD-L1 CPS≥5 according to Median age (IQR),Race(Asian or Non-Asian),Region (Asia or United States and Canada or Rest of world),Primary tumour location at initial diagnosis (GC or GEJC or EAC), the value of Tumour cell PD-L1 expression, Eastern Cooperative Oncology Group performance status(0 or 1),Prior surgery(yes or no), the number of Organs with metastases, Signet ring cell carcinoma(yes or no), Lauren classification (Intestinal type or Diffuse type or Mixed or Unknown), MSI status (MSS or MSI-H or Not reported or invalid),Chemotherapy regimen(FOLFOX or XELOX),Disease stage (Metastatic or Locally advanced or Locally recurrent), Site of metastases (Liver Or Peritoneum or CNS) according to the survival of subgroups of patients in CheckMate 649. Unfortunately,all subgroup analysis factors are all not likely to be cost effective when the payment threshold Less than or equal to \$207659 per QALY.

#### 4. Discussion

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

Fluoropyrimidine plus platinum-based chemotherapy is a first-line treatment for unresectable advanced or metastatic human epidermal growth factor receptor 2 (HER2) negative gastric and GEJ adenocarcinoma, but its efficacy is poor. The study subjects included in CheckMate 649 are patients with advanced/metastatic gastric cancer/gastroesophageal junction cancer/oesophageal adenocarcinoma with negative HER2. Nivolumab plus chemotherapy was compared with chemotherapy to evaluate whether Nivolumab plus chemotherapy could be used as first-line therapy for gastric/GEJ/oesophageal adenocarcinoma patients with negative HER2. The result of CheckMate 649 showed that Nivolumab plus chemotherapy had significantly improved median survival time and median progression-free survival time compared to chemotherapy. Although Nivolumab plus chemotherapy has considerable efficacy in patients with gastric/GEJ/oesophageal adenocarcinoma, economic factors cannot be ignored. Many cancer patients are often forced to ignore the most effective drugs for their treatment because of high drug prices and treatment costs. Therefore, in order to avoid wasting medical resources, it is necessary to conduct a cost-benefit analysis. Based on CheckMate 649 clinical trials and the latest population data and drug prices in USA, Our study is the first to evaluate whether Nivolumab plus chemotherapy is more cost-effective than chemotherapy as first-line treatment for patients with gastric/GEJ/oesophageal adenocarcinoma from the American payers' perspectives. We obtained the data of Nivolumab plus chemotherapy group and chemotherapy group through the clinical trial CheckMate 649, so we could only conduct cost-effectiveness analysis on these two groups. Our analysis shows that with a WTP threshold of \$207659/QALY for the two groups, the Nivolumab plus chemotherapy

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

group may not be cost-effective to be the first-line for gastric/GEJ/oesophageal adenocarcinoma. We also performed subgroup analyses for all the subgroups mentioned in the clinical trials, unfortunately, the subgroup analysis implied that Nivolumab plus chemotherapy was not a cost-effective strategy across all the patient subgroups. One-way sensitivity analysis demonstrated that reducing the cost of drugs was the most influential factor to the result of cost-effectiveness. Since the therapeutic effect of the experimental group was better than that of the control group, and chemotherapy was in the control group, the price largely determines the cost-effectiveness. The lower the price of capecitabine, oxaliplatin, leucovorin and fluorouracil, the lower the cost-effectiveness of the experimental group. There also have been some economic studies on chemotherapy for gastric/GEJ/oesophageal adenocarcinoma, but mainly compared with chemotherapy regimens such as FOLFOX and XELOX. Chemotherapy is much less expensive than immunotherapy in most cases, so it is easier to show cost-effectiveness. Another cost-benefit analysis of Atezolizumab and bevacizumab combination compared with sorafenib in unresectable hepatocellular carcinoma also showed that the immunotherapy group was not cost-effective compared to sorafenib alone (28). Therefore, We conclude that PD-1 inhibitors may be difficult to recommend as cost-effectiveness options for first-line recommendations in advanced gastric/GEJ/oesophageal adenocarcinoma. We found that when the cost of Nivolumab plus chemotherapy was reduced by 23%, respectively, the ICER was \$207659 /QALY which was cost-effective. Therefore, changing the price of Nivolumab plus chemotherapy is an effective feasible strategy to achieve efficient use of them. medical insurance authority could negotiate with pharmaceutical companies to ensure

reasonable drug prices and adjust the medical insurance list to reduce the medical burden on patients. 

5.Limitations

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

Our study has some limitations. First, CheckMate 649 is a phase three randomised controlled trial, and we used this model to simplify the study. For instance, regarding the adverse reactions, we selected the three to four main AEs that would lead to errors. Second, the study's data originated from the CheckMate 649 trial. Due to the limitation of the number of patients included in the trial, we could not perform a larger-scale analysis, and the trial did not provide the follow-up survival data for patients. We relied on the survival data based on the trial and performed a reasonable extrapolation to predict the long-term survival of patients. This will inevitably be different from the data of real-world patients obtained through regular follow-ups. Third, since CheckMate 649 does not disclose the specific health data of patients, our PFS and PD effectiveness were derived from previously published related studies. This may be different from the actual situation of the study. Fourth, we only considered the cost impact and utility reduction caused by the three to four main AEs. The utility reduction caused by specific adverse reactions comes from other published literature, which is in line with the real situation. Fifth, the clinical trial is a multicentred and comprehensive study between different countries and races. The treatment plan of the trial, and especially the follow-up treatment of patients, will be adjusted appropriately according to the specific situation. Therefore, more clinical trials are still required to reduce the study population, follow-up treatment, and other factors that impact the results.

6. Conclusion Overall, from the Americans payers' perspectives, compared with chemotherapy, Nivolumab plus chemotherapy a for the first-line treatment of patients aged 18 years or older who were clinically or pathologically diagnosed with locally advanced or metastatic gastric/GEJ/oesophageal adenocarcinoma may be not a cost-effective choice at a WTP threshold of \$207659 /QALY.

- Acknowledgements 376
- 377 The authors wish to acknowledge Dr Xiang-ping Li, Professor of Department of Pharmacy,
- 378 Xiangya Hospital, Central South University, for his help in tnterpreting the significance of the
- 379 results of the study. And also acknowledge Dr Qin Zhou, Professor of Department of Oncology,
- 380 Xiangya Hospital, Central South University, for support funding to this study.
- Reference: 381
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 382
- 383 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185
- countries. CA Cancer J Clin. 2018;68(6):394-424. 384
- 385 Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, et al. Gastric Cancer,
- 386 Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National
- 387 Comprehensive Cancer Network: JNCCN. 2016;14(10):1286-312.
- 388 Gunderson LL. Gastric cancer--patterns of relapse after surgical resection. Semin Radiat
- 389 Oncol. 2002;12(2):150-61.
- 390 Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric
- cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of 391
- oncology: official journal of the European Society for Medical Oncology. 2016;27(suppl 392
- 393 5):v38-v49.
- 394 Wang FH, Shen L, Li J, Zhou ZW, Liang H, Zhang XT, et al. The Chinese Society of
- 395 Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric
- cancer. Cancer communications (London, England). 2019;39(1):10. 396
- 397 Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2018 (5th

- 398 edition). Gastric Cancer. 2021;24(1):1-21.
- 399 7. Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, et al.
- 400 Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced
- MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised. 401
- double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2017;18(11):1467-82. 402
- 403 Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, et al.
- Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with 404
- 405 metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised,
- placebo-controlled, phase 3 trial. The Lancet Oncology. 2019;20(3):420-35. 406
- Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and 407
- 408 cisplatin with or without cetuximab for patients with previously untreated advanced gastric
- 409 cancer (EXPAND): a randomised, open-label phase 3 trial. The Lancet Oncology.
- 410 2013;14(6):490-9.
- 411 10. Shah MA, Bang YJ, Lordick F, Alsina M, Chen M, Hack SP, et al. Effect of Fluorouracil,
- 412 Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive
- 413 Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. JAMA Oncol.
- 414 2017;3(5):620-7.
- 415 11. Ando K, Kishino Y, Homma T, Kusumoto S, Yamaoka T, Tanaka A, et al. Nivolumab plus
- 416 Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced
- 417 Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. Cancers
- 418 (Basel). 2020;12(7).
- 419 12. Edwards SJ, Wakefield V, Cain P, Karner C, Kew K, Bacelar M, et al. Axitinib,

- 420 cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated
- 421 renal cell carcinoma: a systematic review and economic evaluation. Health technology
- 422 assessment (Winchester, England). 2018;22(6):1-278.
- 13. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line 423
- 424 plus chemotherapy versus chemotherapy alone for advanced gastric,
- 425 gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a
- randomised, open-label, phase 3 trial. The Lancet. 2021;398(10294):27-40. 426
- 427 14. Verma V, Sprave T, Haque W, Simone CB, 2nd, Chang JY, Welsh JW, et al. A
- 428 systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.
- 429 Journal for immunotherapy of cancer. 2018;6(1):128.
- 430 15. Othus M, Bansal A, Koepl L, Wagner S, Ramsey S. Accounting for Cured Patients in
- 431 Cost-Effectiveness Analysis. Value in health: the journal of the International Society for
- Pharmacoeconomics and Outcomes Research. 2017;20(4):705-9. 432
- 433 16. Bullement A, Latimer NR, Bell Gorrod H. Survival Extrapolation in Cancer
- 434 Immunotherapy: A Validation-Based Case Study. Value in health: the journal of the
- International Society for Pharmacoeconomics and Outcomes Research. 2019;22(3):276-83. 435
- 436 17. Yang P. Epidemiology of lung cancer prognosis: quantity and quality of life. Methods in
- 437 molecular biology (Clifton, NJ). 2009;471:469-86.
- 18. Huang M, Lou Y, Pellissier J, Burke T, Liu FX, Xu R, et al. Cost Effectiveness of 438
- 439 Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic
- NSCLC that Expresses High Levels of PD-L1 in the United States. PharmacoEconomics. 440
- 441 2017;35(8):831-44.

- 442 19. Lin S, Luo S, Zhong L, Lai S, Zeng D, Rao X, et al. Cost-effectiveness of atezolizumab
- 443 plus chemotherapy for advanced non-small-cell lung cancer. Int J Clin Pharm.
- 444 2020;42(4):1175-83.
- 20. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. 445
- 446 Recommendations for Conduct, Methodological Practices, and Reporting
- 447 Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.
- Jama. 2016;316(10):1093-103. 448
- 449 21. Thokala P, Ochalek J, Leech AA, Tong TJP. Cost-effectiveness thresholds: the past, the
- 450 present and the future. 2018;36(5):509-22.
- 451 22. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival
- 452 data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res
- 453 Methodol. 2012;12:9.
- 454 23. Liu M, Zhang L, Huang Q, Li N, Zheng B, Cai H. Cost-Effectiveness Analysis Of Ceritinib
- 455 And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive
- 456 Advanced Non-Small Cell Lung Cancer. Cancer Manag Res. 2019;11:9195-202.
- 457 24. Zhang L, Zeng X, Cai H, Li N, Liu M, Qiu L, et al. Cost-effectiveness of second-line
- 458 nivolumab for platinum-treated advanced non-small-cell lung cancer. J Comp Eff Res.
- 459 2020;9(18):1301-9.
- 25. Wang X, Jin L, Cui J, Ma K, Chen X, Li W. Mouse double minute-2 homolog 460
- 461 (MDM2)-rs2279744 polymorphism associated with lung cancer risk in a Northeastern Chinese
- population. Thoracic cancer. 2015;6(1):91-6. 462
- 463 26. Chen HD, Zhou J, Wen F, Zhang PF, Zhou KX, Zheng HR, et al. Cost-effectiveness

analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. J Cancer Res Clin Oncol. 2017;143(2):361-8. 27. Ward MC, Shah C, Adelstein DJ, Geiger JL, Miller JA, Koyfman SA, et al. Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer. Oral Oncol. 2017;74:49-55. 28. Lam SW, Wai M, Lau JE, McNamara M, Earl M, Udeh B. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer. Pharmacotherapy. 2017;37(1):94-103.

486 487 488 489 490 491 Ethics approval 492 This study was based on a literature review and modelling techniques; this study did not require approval by an institutional research ethics board. 493 494 Disclaimer 495 The views expressed are those of the authors. The funding agencies played no role in the study 496 design, data collection and analysis, decision to publish, or manuscript preparation. 497 Provenance and peer review Not commissioned; externally peer reviewed. 498 499 Data sharing statement 500 No additional data are available. 501 Supplemental material 502 Supplemental material for this article is available online. 503 Figures and legends Figure 1. Markov state transition model. 504 505 Figure 2. Tornado diagram for one-way sensitivity analysis. 506 Figure 3. Acceptability Curves. 507 Figure 4. Incremental cost-effectiveness scatterplots.

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

Ethics approval and consent to participate Not applicable Consent for publication Not applicable Availability of data and materials Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. Conflict of interest The authors declare that there is no conflict of interest. **Funding** This study was funded by the Natural Science Foundation of Hunan Province for Young Scholars (No. 2020JJ5957; Project Recipient: QZ). Authors' contributors Mr Zhou and Mr Tang had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Li. Acquisition, analysis, or interpretation of data: Zhou, Tang. Drafting of the manuscript: Zhou, Tang, Li. Critical revision of the manuscript for important intellectual content: Tang. Statistical analysis: Zhou, Tang. Obtained funding: Zhou.

- 530 Administrative, technical, or material support: Zhou, Tang.
- 531 Supervision: Tang.